Eye fluid study in diabetes and cataract patients
Part of Eyes & vision, Hormones & metabolism clinical trials.
This study looks at two proteins (DEL-1 and IL-17) in the fluid inside the eye of people with diabetes who are having cataract surgery. It aims to understand how these proteins might be linked to eye health in diabetes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with a cataract and are scheduled for cataract surgery.
- You have no other eye problems besides the cataract.
- You have had type 2 diabetes for at least 5 years (if you are in the diabetic group).
- You have not had any previous eye surgery.
- You do not have inflammatory eye diseases like uveitis.
- You are not taking steroid medications (either as eye drops or by mouth).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how diabetes and eye inflammation are linked in people with diabetic retinopathy (damage to the retina caused by diabetes). By studying fluid samples from the eye during cataract surgery, researchers hope to find new ways to treat or prevent this condition.
This study tests a new approach aimed at improving diabetic eye disease (diabetic retinopathy). It may help by changing inflammation and related processes in the eye, especially in people who have diabetes and eye changes.
This trial measures eye fluid flow during cataract or glaucoma surgery. It aims to help doctors predict and improve surgery results.
This study collects eye fluid and tissue samples during planned cataract or combined cataract-glaucoma surgery to analyze differences between people with and without glaucoma. It may help researchers understand eye disease better.
This study looks for specific eye findings (“biomarkers”) in people with type 2 diabetes using eye imaging. It may help researchers better understand diabetic retinopathy and how to detect it earlier or more accurately.
This study follows patients with diabetic eye swelling (a complication of diabetes affecting the macula, the part of your eye needed for detailed vision) who are receiving anti-VEGF injections—a standard treatment that reduces abnormal blood vessel growth. Researchers will measure how well your retina (the light-sensitive tissue in your eye) recovers and functions over time.
Hear when a new Diabetic Group (n=30) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.